For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
In this report, in the last several years, the EMEA (Europe, Middle East and Africa) market of Flu Vaccine developed rapidly, with an average growth rate of 7.50%. In 2016, EMEA (Europe, Middle East and Africa) Revenue of Flu Vaccine is nearly 750 M USD; the actual sales are about 77 M Doses.
Influenza vaccines, also known as flu shots, are vaccines that protect against influenza. A new version of the vaccine is developed twice a year as the influenza virus rapidly changes. Most provide modest to high protection against influenza; however, each year this varies. Evidence in adults over 65 years old is poor. They decrease the number of missed days of work by a half day on average. Vaccinating children may protect those around them.
The classification of Flu Vaccine includes Whole Virus Vaccines, Split Virus Vaccines, Subunit Vaccines and Live Attenuated Virus Vaccines, and the proportion of Whole Virus Vaccines in 2016 was about 43%, and the proportion was in decreasing trend from 2012 to 2016.
Flu Vaccine is widely used for Children (6 months to 3 years) and for Adults and Children over 3years. The most proportion of Flu Vaccine is For Adults and Children over 3years, and the proportion in 2016 was about 75%.
The Europe in the EMEA was the largest consumption place, with a consumption market share nearly 80% in 2016. And in the major countries we mentioned in the report, Germany was the largest consumption place with the consumption market share of 12%. Following Russia, France was the second largest consumption region, with the proportion of 11%.
Market competition is not intense. CSL, GSK, Sanofi Pasteur, Mylan, AstraZeneca, Pfizer and Johnson & Johnson, etc. are the leaders of the industry in the EMEA, with high-end customers in the Flu Vaccine market.
Geographically, this report split Europe into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Flu Vaccine for these regions, from 2014 to 2026 (forecast), including
- Germany
- UK
- France
- Russia
- Benelux
- Italy
- Spain
Europe Flu Vaccine market competition by top manufacturers/players, with Flu Vaccine sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
- CSL
- GSK
- Sanofi Pasteur
- Mylan
- AstraZeneca
- Pfizer
- Johnson & Johnson
On the basis of product, this report displays the sales volume (K Units), revenue (Million USD), product price (USD/Unit), market share and growth rate of each type, primarily split into
- Whole Virus Vaccines
- Split Virus Vaccines
- Subunit Vaccines
- Live Attenuated Virus Vaccines
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K Units), market share and growth rate of Flu Vaccine for each application, including
- For Children (6 months to 3 years)
- For Adults and Children over 3 years
If you have any special requirements, please let us know and we will offer you the report as you want.